|
Epigenomic fingerprint in late-stage cancers suggests a common pathway
A test based on H3K36me3 loss, a newly identified epigenomic fingerprint, may help providers improve diagnosis and treatment of advanced disease across a wide variety of cancer types.
Molecular data helps to better classify patients with glioma
A new approach that categorizes brain tumors according to the presence of three genetic alterations — 1p/19q codeletion, IDH mutation and TERT mutation — can be used to sort gliomas into five categories, each with different clinical features and outcomes.
New regimen offers longer disease control and a decreased risk of relapse for patients with CLL
Ibrutinib and chemotherapy (bendamustine and rituximab, known as BR) reduced the risk of death or cancer progression by almost 80 percent in patients with previously treated CLL or SLL compared with use of BR alone.
Studies tackle Cologuard questions
Cologuard, a noninvasive multitarget stool screening test for colorectal cancer, has been found to have a sensitivity for cancer equal to colonoscopy. But questions remain about the test's role in the colorectal cancer screening algorithm.
See all Cancer Clinical Trials at Mayo Clinic |
|
Mayo Clinic Acute and Chronic Leukemias 2015: A Case-Based Discussion of New Developments and Novel Drugs
Sept. 12, 2015, in Phoenix
This regional meeting for physicians and nurse practitioners focuses on diagnosis and treatment of acute myeloid and lymphoid leukemia.
18th Annual Mayo Clinic Internal Medicine Update: Sedona October Session 2015
Oct. 15-18, 2015, in Sedona, Ariz.
Focus includes practical updates on subspecialty topics, including anesthesiology, allergy, cardiovascular diseases, consultative medicine, dermatology, endocrinology, gastroenterology, hematology, infectious diseases, nephrology, neurology, otolaryngology, palliative, preventative medicine, psychiatry, pulmonary, urology and women's health.
Cutaneous Oncology Symposium 2015
Oct. 23-24, 2015, in Amelia Island, Fla.
This multidisciplinary review of nonmelanoma skin cancer (NMSC) and malignant melanoma includes current standards of practice and treatment of NMSC, such as Merkel cell carcinoma, and high-risk basal cell or squamous cell carcinoma and advances in melanoma treatment.
See all Hematology & Oncology Continuous Professional Development courses |
